Fig. 7: Overexpression of circCYP24A1 suppresses RCC progression in vivo.

Luciferase-expressing 786-O cells transfected with LV-NC, LV-circCYP24A1, LV-cirCYP24A1+miR-421 mimic, and LV-circCYP24A1+sh-CMTM4 were used to establish subcutaneous xenograft models (N = 5). A Tumor growth was monitored using in vivo bioluminescence imaging. B Weights of subcutaneous 786-O tumors were evaluated 21 days after implantation. C Relative luciferase values of subcutaneous 786-O tumors were assessed. D Subcutaneous 786-O tumors are shown. E Immunohistochemical staining for CMTM4, N-cadherin, p-ERK, and p-AKT was performed in the subcutaneous tumors from the 4 groups.